All companies › NRIX

NRIX · Nurix Therapeutics, Inc.

Everything on this page is public record — SEC Form 4 filings and congressional disclosures — alongside any INSIDER SCANNER research case for this company.

Open-market buys0
Open-market sells3
Research cases0
Last filing2026-10-15

Insider flow: Selling only — a count of disclosed transactions, not a rating or a recommendation.

Insider transaction timeline

Every reported transaction, positioned by trade date. Purchases sit above the axis, sales below; circle area is proportional to dollar value. No share-price line is drawn — this feed carries transaction prices only, and a price history inferred from them would imply market data the filings do not contain.

Open-market purchase Open-market sale
2026-10-02 — Ring Christine · sold 5,786 @ $23.19 2026-10-14 — GREGORY JULIA P · sold 22,583 @ $23.40 2026-10-15 — Hansen Gwenn · sold 1,452 @ $25.00
2026-10-022026-10-15

Insider participation

One row per insider, one cell per reported transaction, shaded by value. Repeat buying and activity clustered in time are visible at a glance.

Ring Christine Chief Legal Officer
GREGORY JULIA P Director
Hansen Gwenn Chief Scientific Officer
Included with a free account

The analysis built on top of these filings

The filings above are public record and stay public here. What an account adds for $NRIX is the reading of them — and for this company, that is what the list below says it is, no more.

  • Transaction timelineThe [{'transaction_date': '2026-10-15', 'insider_name': 'Hansen Gwenn', 'insider_title': 'Chief Scientific Officer', 'transaction_type': 'Open-market sell', 'shares': 1452.0, 'price': 25.0, 'value': 36300.0, 'is_buy': False}, {'transaction_date': '2026-10-14', 'insider_name': 'GREGORY JULIA P', 'insider_title': 'Director', 'transaction_type': 'Open-market sell', 'shares': 22583.0, 'price': 23.4038, 'value': 528528.02, 'is_buy': False}, {'transaction_date': '2026-10-02', 'insider_name': 'Ring Christine', 'insider_title': 'Chief Legal Officer', 'transaction_type': 'Open-market sell', 'shares': 5786.0, 'price': 23.1851, 'value': 134148.99, 'is_buy': False}] reported transactions plotted over the window rather than listed, so concentration is visible.

Not available for NRIX today: no reported open-market purchases in this window, so there is no insider cost basis to compute; no research case — nothing here has cleared the scoring threshold. Both appear on this page on their own if that changes.

A free account opens all of it.

Not financial advice. This page reports public filings and past research output. It is not a recommendation to buy or sell, and no price target here is a prediction. Trade at your own risk.